Cannabinoids for Scleroderma
Project CBD
OCTOBER 10, 2019
Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma. Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials.
Let's personalize your content